# Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia

> **NCT03027609** · PHASE2 · COMPLETED · sponsor: **Aridis Pharmaceuticals, Inc.** · enrollment: 158 (actual)

## Conditions studied

- Pseudomonas Aeruginosa Pneumonia

## Interventions

- **DRUG:** AR-105
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03027609
- **Lead sponsor:** Aridis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-29
- **Primary completion:** 2019-04-25
- **Final completion:** 2019-04-25
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2022-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03027609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03027609, "Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03027609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*